{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Complete Response according to International Myeloma Working Group uniform response criteria. CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.","groups":[{"description":"Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.","id":"OG000","title":"A: Allogeneic Stem Cell Transplant"},{"description":"Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.","id":"OG001","title":"B: Autologous Stem Cell Transplant"},{"description":"Group B Expansion on Bortezomib Maintenance: Autologous Only.","id":"OG002","title":"BE: Group B Expansion"}],"populationDescription":"Patients were in very good partial response at the time on enrollment without sufficient plasma cells in bone marrow to be able to perform assay for molecular response.","reportingStatus":"POSTED","timeFrame":"End of 2 year, post transplant follow-up","title":"Molecular Complete Response (CR) Rates in Patients With Multiple Myeloma","type":"SECONDARY"}